Linvoseltamab Receives EU Approval for Relapsed/Refractory Multiple Myeloma

Linvoseltamab, now Lynozyfic, wins EU's conditional OK for RRMM

The European Commission (EC) has conditionally approved Regeneron Pharmaceuticals’ linvoseltamab, now Lynozyfic, to treat adults with relapsed or refractory multiple myeloma (RRMM). With this approval, RRMM patients in the European Union who have already received at least three other prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and continued to experience disease progression on t…

Linvoseltamab Receives EU Approval for Relapsed/Refractory Multiple Myeloma

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.

Impact of pre-transplant serum levels of activin A, activin B, IGF-1 and IL-6 on transplant outcomes and survival in patients with multiple myeloma: a prospective study

OBJECTIVE: This prospective study aimed to assess the impact of activin A/B, interleukin 6 (IL-6) and insulin-like growth factor-1 (IGF-1) on end-organ

Lynozyfic receives EU approval for relapsed multiple myeloma treatment

New therapy offers hope for patients with limited option